Daxor Corporation Announces European Patent Approval For Max-100 Injection Kit For Use With Blood Volume Analyzer BVA-100

NEW YORK--(BUSINESS WIRE)--July 20, 2006--Daxor Corporation (AMEX: DXR - News), a medical instrumentation and biotechnology company, received notification from the European Patent Office that it has received a patent for its injection kit system, the Max-100, for use with the Blood Volume Analyzer BVA-100.

MORE ON THIS TOPIC